Chronic Kidney Disease
Progressive loss of kidney function
What it is
Chronic kidney disease is a sustained reduction in kidney function (eGFR < 60 for ≥ 3 months) and/or kidney damage (such as albumin in the urine). It is usually silent early and is staged by eGFR and albuminuria together.
Why it matters
CKD is common, often undetected, and a powerful multiplier of cardiovascular risk — most people with CKD die of cardiovascular disease before reaching kidney failure. Early detection and treatment can markedly slow progression and reduce events.
What BioSignal knows about treating this
What works for Chronic Kidney Disease
BioSignal’s clinical summary, most important first.
- Blood pressure control (ACE inhibitors / ARBs when albuminuria is present)
- Glucose control in diabetes
- SGLT2 inhibitors (slow progression, even in non-diabetic CKD)
- Lipid and cardiovascular risk management
- Avoiding nephrotoxins (e.g., NSAID overuse)
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Blood Pressure MedicationHigh confidence
Among the highest-value medicines ever made. The evidence isn't the problem — about half of people stop taking them, and that's where the strokes are.
- SGLT2 InhibitorsHigh confidence
Modest glucose lowering but proven heart-failure and kidney protection, even without diabetes; manageable risks.
- MagnesiumModerate confidence
Genuinely effective for a few specific things — eclampsia (in hospital), constipation, migraine prevention, and a modest blood-pressure effect. The reasons most people actually buy it — sleep, cramps, anxiety — are the weakest part of the evidence.
- AnticoagulantsHigh confidence
Among the most effective drugs in medicine — roughly a two-thirds reduction in AF stroke. The complexity is not whether they work; it is which one, for whom, and what else you are taking.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Diabetes (the leading cause)
- High blood pressure
- Older age
- Cardiovascular disease
- Family history
- Obesity and metabolic syndrome
How it's diagnosed
Diagnosed and staged with two measures together: eGFR (from creatinine, sometimes cystatin C) and urine albumin-to-creatinine ratio (UACR). Both are needed — significant CKD can exist with a normal eGFR if albuminuria is present.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related peptide families
Related body systems
Frequently asked questions
Can chronic kidney disease be slowed?
Yes. Controlling blood pressure and glucose, using ACE inhibitors/ARBs when there's albuminuria, and adding SGLT2 inhibitors can meaningfully slow progression — the earlier, the better.
Why measure urine albumin if my eGFR is normal?
Because albuminuria can reveal kidney damage before eGFR drops, and it independently raises cardiovascular and kidney risk. eGFR and UACR are read together.
Evidence summary
Slowing CKD with blood-pressure control, RAAS blockade for albuminuria, and SGLT2 inhibitors is established by large randomized trials (including in non-diabetic CKD); CKD's amplification of cardiovascular risk is well documented.
References & sources
- KDIGO Clinical Practice Guideline for CKD
- SGLT2 kidney-outcome trials (CREDENCE, DAPA-CKD)
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback